Castle Biosciences (CSTL) Gross Profit (2018 - 2026)

Castle Biosciences has disclosed Gross Profit across 9 years of filings, most recently posting $63.1 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $63.1 million, down 11.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $264.7 million (down 6.91% YoY), and the FY2025 annual result was $273.2 million, changed 0.49% from the prior year.
• Gross Profit came in at $63.1 million for Q1 2026 at Castle Biosciences, down from $68.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $72.5 million in Q2 2024 to a low of $20.9 million in Q1 2022.
• The 5-year median for Gross Profit is $59.1 million (2024), against an average of $52.2 million.
• Across the five-year window, Gross Profit jumped 86.33% in 2023 and retreated 11.81% in 2026, its largest moves.
• Castle Biosciences' Gross Profit stood at $28.8 million in 2022, then soared by 86.33% to $53.7 million in 2023, then surged by 30.6% to $70.1 million in 2024, then declined by 2.04% to $68.7 million in 2025, then fell by 8.08% to $63.1 million in 2026.
• The last three Gross Profit figures came in at $63.1 million (Q1 2026), $68.7 million (Q4 2025), and $64.3 million (Q3 2025), per Business Quant data.